Louis H. Morrone - 30 Jun 2023 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role: EXECUTIVE VICE PRESIDENT
Signature: /s/ Louis H. Morrone by Jessica H. Paik, Attorney-in-Fact
Issuer symbol: ABT
Transactions as of: 30 Jun 2023
Transactions value $: $-60,615
Form type: 4
Filing time: 05 Jul 2023, 11:55:29 UTC
Previous filing: 02 Mar 2023
Next filing: 23 Feb 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABT	Common shares without par value	Award	$0	+1,815	+3.38%	$0.000000	55,471	30 Jun 2023	Direct	F1
transaction	ABT	Common shares without par value	Tax liability	$-60,615	-556	-1%	$109.02	54,915	01 Jul 2023	Direct
holding	ABT	Common shares without par value						2,481	30 Jun 2023	Profit Sharing Trust	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABT	Option (right to buy)	Award	$0	+7,100		$0.000000	7,100	30 Jun 2023	Common Shares	7,100	$108.52	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2	Balance in the Abbott Laboratories Stock Retirement Trust as of June 30, 2023.
F3	Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 2,366 on June 30, 2024, 2,367 on June 30, 2025, and 2,367 on June 30, 2026.